Dynavax Technologies Corporation has initiated a Phase Ib clinical trial of N8295, a universal flu vaccine candidate.
The trial will assess the safety and efficacy of N8295 in combination with Novartis' investigational H5N1 avian influenza vaccine.
It will involve 15 patients split into three groups, each of which will receive a different dose of N8295 in combination with the same dose of H5N1 vaccine.
The patients will receive two immunisations, separated by one month, and will be assessed for about one year.
The preliminary data of the Phase Ib trial is expected to be available in the early 2011.
Dynavax plans to use the data from the trial to partner with Novartis for joint development and commercialisation of the product.